Table 1.
Evolution of body weight, plasma lipids and glucose levels, HR, SBP, and pulse pressure in mice
| Weight, g | Total cholesterol, mmol/l | LDL cholesterolmmol/l | HDL cholesterol, mmol/l | Triglycerides, mmol/l | Glucose, mmol/l | Average 24-h HR, beats/min | SBP, mmHg | Pulse, mmHg | |
|---|---|---|---|---|---|---|---|---|---|
| 3-mo WT | 27 ± 1 (12) | 2.1 ± 0.2 (4) | 0.1 ± 0.1 (4) | 1.6 ± 0.1 (4) | 1.2 ± 0.2 (4) | 18.1 ± 2.7 (4) | 543 ± 15 (6) | 137 ± 6 (6) | 31.0 ± 1.7 (6) |
| 3-mo ATX | 27 ± 1 (15) | 16.2 ± 1.1† (4) | 9.8 ± 0.5† (4) | 1.9 ± 0.1 (4) | 7.8 ± 0.6† (4) | 16.2 ± 1.7 (4) | 522 ± 10 (10) | 147 ± 2† (23) | 31.6 ± 0.8 (23) |
| 6-mo WT | 38 ± 1† (20) | 2.3 ± 0.2 (9) | 0.7 ± 0.2 (9) | 1.2 ± 0.1 (9) | 0.8 ± 0.1 (4) | 24.0 ± 2.4 (9) | 532 ± 12 (7) | 127 ± 3 (7) | 30.3 ± 1.9 (6) |
| 6-mo ATX | 31 ± 1*‡ (20) | 16.1 ± 1.0* (9) | 10.1 ± 0.8* (9) | 1.6 ± 0.1* (9) | 7.4 ± 0.8* (9) | 13.8 ± 2.2* (9) | 504 ± 15 (7) | 149 ± 4* (11) | 32.9 ± 1.0 (6) |
| 6-mo ATX + IVA | 33 ± 1 (11) | 16.1 ± 1.9 (4) | 10.3 ± 1.3 (4) | 1.9 ± 0.1 (4) | 7.1 ± 0.6 (4) | 9.6 ± 1.3 (4) | 434 ± 10§ (6) | 149 ± 6 (6) | 33.7 ± 1.0 (11) |
| 6-mo ATX + METO | 32 ± 1 (11) | 20.2 ± 1.0§ (4) | 13.5 ± 0.5§ (9) | 1.7 ± 0.1 (4) | 9.0 ± 0.6 (4) | 11.0 ± 1.6 (4) | 439 ± 7§ (6) | 150 ± 5 (6) | 37.1 ± 2.1 (6) |
| 6-mo ATX + PT | 31 ± 1 (6) | 17.8 ± 2.1 (5) | 11.4 ± 2.0 (5) | 1.6 ± 0.1 (5) | 7.5 ± 0.8 (5) | 15.4 ± 3.0 (5) | 516 ± 30 (3) | 159 ± 4 (6) | 33.0 ± 1.2 (6) |
Results are means ± SE of (n) mice. HR, heart rate (telemetry); SBP, systolic blood pressure (tail-cuff); Pulse, pulse pressure (tail-cuff); WT: wild-type mice; ATX: LDLr−/−:hApoB+/+ mice; ATX + IVA: LDLr−/−:hApoB+/+ mice treated with ivabradine (15 mg · kg−1 · day−1); ATX + METO: LDLr−/−:hApoB+/+ mice treated with metoprolol (80 mg · kg−1 · day−1); ATX + PT: LDLr−/−:hApoB+/+ mice subjected to 3 mo of voluntary physical training.
†
P < 0.05 vs. 3-mo WT;
*
P < 0.05 vs. 6-mo WT;
‡
P < 0.05 vs. 3-mo ATX;
§
P < 0.05 vs. 6-mo ATX.